ClinicalTrials.Veeva

Menu
B

Bay Area Arthritis and Osteoporosis | Brandon, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

M5049
GDC-0853
Filgotinib
Certolizumab
Apremilast
Ustekinumab
Ianalumab
Afimetoran
Tofacitinib
Deucravacitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 18 total trials

A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. (NEPTUNUS-Ext)

The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously...

Enrolling
Sjogrens Syndrome
Drug: Ianalumab (VAY736)
Other: Placebo
Locations recently updated

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Enrolling
Systemic Lupus Erythematosus
Other: Placebo
Drug: Afimetoran

The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).

Active, not recruiting
Systemic Lupus Erythematosus
Other: Placebo
Drug: Standard-of-care treatment

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA...

Active, not recruiting
Psoriatic Arthritis
Drug: Apremilast
Drug: Deucravacitinib

The purpose of this study is to evaluate the efficacy of combination therapy with nipocalimab and certolizumab compared to certolizumab monotherapy.

Active, not recruiting
Arthritis, Rheumatoid
Drug: Placebo
Drug: Nipocalimab

The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus...

Enrolling
Systemic Lupus Erythematosus
Drug: M5049 medium dose
Drug: M5049 low dose

The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: Placebo
Drug: Enpatoran low dose

A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with activ...

Active, not recruiting
Sjogren Syndrome
Other: Placebo
Biological: VAY736

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Bristol-Myers Squibb (BMS) logo
Genentech logo
Novartis logo
Amgen logo
Gilead Sciences logo
Horizon Therapeutics logo
Merck KGaA (EMD Serono) logo
Merck KGaA (EMD Serono) logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems